Other Information.
−Removed: March 15, 2024 , our
−Removed: Chief Medical Officer ,
−Removed: Mark Schoenberg ,
−Removed: terminated the trading plan previously entered into on
−Removed: December 26, 2023 , to sell up to
−Removed: 30,000 ordinary shares.
−Removed: This plan was intended to satisfy the affirmative defense conditions of Rule
−Removed: 1 (c) under the Exchange Act.
The following exhibits are filed as part of this report:
1 unchanged sentence
001-38079), filed with the SEC on May 18, 2017).
−Removed: Form of July 2023 Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant ’s Current Report on Form 8-K (File No.
−Removed: 001-38079), filed with the SEC on July 27, 2023).
−Removed: Amendment to Form of Performance-Based Restricted Stock Unit Grant Notice under the UroGen Pharma Ltd.
−Removed: 2017 Equity Incentive Plan.
−Removed: Form of Performance Stock Award Grant Notice and Performance Stock Award Agreement under the UroGen Pharma Ltd.
−Removed: Israeli Sub-Plan to 2017 Equity Incentive Plan.
−Removed: License and Supply Agreement, dated as of January 16, 2024, by and between UroGen Pharma Ltd.
−Removed: and Medac Gesellschaft fü r klinische Spezialpr ä parate m.b.H.
−Removed: (incorporated by reference to Exhibit 10.32 to the Registrant's Form 10-K (File No.
−Removed: 001-38079), filed with the SEC on March 14, 2024).
−Removed: Amended and Restated Loan Agreement, dated as of March 13, 2024, by and among UroGen Pharma, Inc., as the borrower, and a credit party, Urogen Pharma Ltd.
−Removed: as Parent, and a Credit Party, the other guarantors signatory hereto or otherwise party hereto from time to time as additional Credit Parties, BioPharma Credit PLC as collateral agent, BPCR Limited Partnership as a lender and BioPharma Credit Investments V (Master) LP as a lender (incorporated by reference to Exhibit 10.35 to the Registrant's Form 10-K (File No.
−Removed: 001-38079), filed with the SEC on March 14, 2024).
+Added: Form of June 2024 Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-38079), filed with the SEC on June 18, 2024).
+Added: UroGen Pharma Ltd.
+Added: 2019 Inducement Plan, as amended.
+Added: UroGen Pharma Ltd.
+Added: 2024 Non-Employee Director and Officer Compensation Policy (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 8, 2024).
+Added: 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 8, 2024).
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
The cover page from the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL
−Removed: Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
−Removed: Certain information in this exhibit has been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type of information that the registrant treats as private or confidential.
+Added: Management contract or compensatory plan.
The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.
1 unchanged sentence
UroGen Pharma Ltd.
+Added: August 13, 2024
/s/ Elizabeth Barrett
2 unchanged sentences
(Principal Executive Officer)
+Added: August 13, 2024
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.